Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

Published Erratum

Michael S Anglesio et al. PLoS One. 2013.

. 2013 Sep 27;8(9):10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.

doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

Abstract

[This corrects the article on p. e72162 in vol. 8.].

Competing Interests: No competing interests declared.

Type-specific cell line models for type-specific ovarian cancer research.
Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. Anglesio MS, et al. PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. PLoS One. 2013. PMID: 24023729 Free PMC article.

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG. Karnezis AN, et al. J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21. J Pathol. 2016. PMID: 26356327 Free PMC article.